About: Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
MNMD NASDAQ Mind Medicine Inc
Mind Medicine Inc share price
Atividade de preço de MNMD
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
MNMD price performance
quote.marketSignals